



11000 U.S. PTO  
09/781491  
02/13/01

FORM PTO-1449 (Substitute)	ATTY. DOCKET NO.	SERIAL NO. 09/781,491
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)	APPLICANT Dallas L. Cloutre, et al.	
	FILING DATE 02/10/01	GROUP 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,914,326	06/1999	McCarty, et al.	514	188	
	AB	5,783,603	07/1998	Majeed, et al.	514	574	
	AC	5,656,314	08/1997	Moffett, et al.	426	271	
	AD	5,626,849	05/1997	Hastings, et al.	424	195.1	
	AE	3,993,668	11/1976	Guthrie, et al.	260	343.6	
	AF	3,919,254	11/1975	Guthrie, et al.	260	343.6	
	AG	3,767,678	10/1973	Guthrie, et al.	260	343.6	
	AH	3,764,692	10/1973	Lowenstein	424	279	
	AI						
	AJ						
AK							

11000 U.S. PTO  
09/781491  
02/13/01

FOREIGN PATENT DOCUMENTS

AL						
AM						
AN						
AO						
AP						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	see attached sheet					
AS						
AT						

EXAMINER [Signature]	DATE CONSIDERED January 28, 2002
-------------------------	-------------------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## LIST OF PRIOR ART CITED BY APPLICANT

Sheet 2 of 2

Dallas L. Clouatre, et al.

METHODS AND PHARMACEUTICAL PREPARATIONS FOR NORMALIZING BLOOD PRESSURE WITH (-)-HYDROXYCITRIC ACID

02/10/01

## OTHER PRIOR ART

Benson S, Vance-Bryan K, Raddatz J. Time to patient discontinuation of antihypertensive drugs in different classes. Am J Health Syst Pharm. 2000 Jan 1;57(1):51-4.

Cusin I, Rohner-Jeanrenaud F, Terrettaz J, Jeanrenaud B. Hyperinsulinemia and its impact on obesity and insulin resistance. Int J Obes Relat Metab Disord. 1992 Dec;16 Suppl 4:S1-11.

Ishihara K, Oyaizu S, Onuki K, Lim K, Fushiki T. Chronic (-)-hydroxycitrate administration spares carbohydrate utilization and promotes lipid oxidation during exercise in mice. J Nutr. 2000 Dec;130(12):2990-5.

McCarty MF. Toward a wholly nutritional therapy for type 2 diabetes. Med Hypotheses 2000 Mar;54(3):483-487.

McCarty MF. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Medical Hypotheses 1994;42:215-225.

Preuss HG, Burris JF. Adverse metabolic effects of antihypertensive drugs. Implications for treatment. Drug Saf. 1996 Jun;14(6):355-64.

Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000 Mar 30;342(13):969-70.

Sullivan AC, Triscari J. Metabolic regulation as a control for lipid disorders. I. Influence of (-)-hydroxycitrate on experimentally induced obesity in the rodent. American Journal of Clinical Nutrition 1977;30:767.

Sullivan, Ann C. and Joseph Triscari. Possible interrelationship between metabolite flux and appetite. In D. Novin, W. Wyriwicka and G. Bray, eds., Hunger: Basic Mechanisms and Clinical Implications (New York: Raven Press, 1976) 115-125.

Wayne C. Jones  
January 28, 2002